Having trouble accessing articles? Reset your cache.

Inscopix: scoping out better preclinical models via live brain imaging

Inscopix uses brain imaging to make better preclinical models for CNS diseases

With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in neural circuits, rather than behavioral readouts, as a measure of disease.

Founder and CEO Kunal Ghosh believes the notorious track record of rodent models of neurological diseases is rooted in the inadequacy of standard behavioral tests used to reflect symptoms or to read out disease biology.

“For better or worse, all preclinical models cause skepticism, but I think we can do better with a circuit-based

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers